Medicine Recommendations

Monotherapy for treating type 2 diabetes (NICE TA390)

NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Gouty arthritis (NICE TA 281 - terminated appraisal)

NICE TA281 - Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)

Juvenile idiopathic arthritis (systemic) (NICE TA302)

NICE TA302 - Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)

Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy

NICE TA 351 - Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (NICE TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (NICE TA615)

For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication.

This recommendation only covers the use of Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex) oromucosal spray for the indication of moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication

Cannabis-based medicinal products NG144

Refractory neuropathic pain

Cannabis-Based Products for the management of patients with chronic pain

Cannabis-based medicinal products NG144

Cannabis-Based Products for the management of intractable paediatric epilepsy

Localised neuropathic pain (as per LSCMMG Guidelines)

Hand and Knee Osteoarthritis (as per LSCMMG Guidelines)

Trigeminal Neuralgia (as per LSCMMG Guidelines)

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Prophylaxis of bipolar disorder unresponsive to lithium

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Postpartum haemorrhage

Treatment of schizophrenia in adult patients 

Dry eye disease

Pain: Anti-inflammatory

Treating focal onset seizures in epilepsy (NICE TA753)

NICE TA753 - Cenobamate for treating focal onset seizures in epilepsy

Rheumatoid arthritis (LSCMMG pathway)